Your session is about to expire
← Back to Search
AT-100 for Bronchopulmonary Dysplasia
Study Summary
This trial will test if a new drug can reduce the occurrence of a lung disease in premature babies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My baby was born prematurely, between 23 and 29 weeks of pregnancy.I have major birth defects affecting my heart and lungs.You have a current order that says not to resuscitate (bring back to life).The birth mother has a serious illness or has been exposed to something that may weaken the immune system, such as HIV or chemotherapy.My newborn received a surfactant dose and can get the first AT-100 or air-sham dose within 96 hours of birth.My birth mother has an active Hepatitis B, C, or E infection.I currently have air leaks in my lungs.I was re-intubated after my Curosurf® dose but meet other required conditions.My birth mother has a history of drug or alcohol abuse, excluding marijuana.My baby might receive a special lung treatment soon or just had one.I had COVID-19 symptoms and a positive test around my child's birth.My birth mother has an active CMV infection.I am not allergic to any ingredients in the trial medication.My baby was born between 25 and 29 weeks of pregnancy.My birth weight was either below 400g or above 1,800g.You received AT-100 or a fake treatment before it was approved to move to the next level of dosage.I am currently on a breathing machine.
- Group 1: Phase 1b open-label AT-100
- Group 2: Phase 1b open-label air-sham
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor open to participants of 45 years or older?
"According to the entry requirements, only those between 0 Minutes and 96 Hours old are eligible. Additionally, there exists 71 clinical trials for minors and 108 studies tailored towards elderly patients."
How many locations have been designated for the performance of this trial?
"Currently, 12 sites are distributing the medication and participating in this trial. While Nashville, Boston, and Los Angeles are three of these locations, there are also 9 additional ones available. To minimize travel burdens while taking part in this study it is encouraged to select a centre close by."
Has AT-100 obtained clearance from the FDA?
"AT-100's safety rating is 1, as it has only been through the initial stages of clinical trials and therefore lacks substantial data to back its efficacy or security."
Is this research team actively seeking participants?
"Affirmative. Clinicaltrials.gov attests that this clinical trial, started on September 1st 2021, is still actively recruiting participants. The 36 required patients should be sourced from 12 separate medical centres."
What constitutes the criteria to become an eligible participant in this clinical trial?
"Qualified participants must be afflicted with Bronchopulmonary Dysplasia and range between 0 Minutes to 96 Hours of age. This trial is attempting to enroll a total of 36 patients."
How many patients have been accepted into this research experiment?
"Affirmative. According to clinicaltrials.gov, recruitment for this medical study is ongoing; it was first posted on September 1st 2021 and last edited on October 20th 2022 with the goal of enrolling 36 volunteers across 12 different sites."
Share this study with friends
Copy Link
Messenger